In a significant milestone for the rapidly evolving field of artificial intelligence in medicine, Chai Discovery, a pioneering start-up focused on developing AI-driven drugs, has secured a staggering $400 million in funding. This substantial investment is a testament to the growing confidence of investors in the potential of AI to revolutionize the pharmaceutical industry. Founded by a team of seasoned experts in the field, Chai Discovery aims to leverage cutting-edge AI technology to accelerate the discovery of new treatments for a wide range of diseases. With this major influx of capital, the company is poised to further accelerate its research and development efforts, potentially paving the way for breakthroughs in disease prevention and treatment.
Chai Discovery, an A.I. Drug Start-Up, Raises $400 Million The New York Times
